Am I a Candidate for TIL Therapy?
Understanding the strict medical, surgical, and physiological requirements for Tumor-Infiltrating Lymphocyte (TIL) therapy. A transparent guide to help you and your oncologist evaluate this option.
Why TIL Eligibility is Strictly Evaluated
TIL therapy is not a simple outpatient procedure. It is an intensive, multi-step cellular therapy that requires surgery, hospitalization, and the administration of high-dose Interleukin-2 (IL-2). Because of this complexity, treating centers apply rigorous eligibility criteria to ensure patient safety and maximize the likelihood of a meaningful response.
Eligibility is generally evaluated across four critical pillars. A patient must typically meet the requirements of all four to be considered a viable candidate.
The 4 Pillars of TIL Therapy Eligibility
1. Disease Status & Prior Treatments
- Diagnosis of unresectable or metastatic melanoma.
- Documented disease progression after treatment with a PD-1 blocking antibody (e.g., pembrolizumab, nivolumab).
- If the tumor is BRAF V600 mutation-positive: documented progression after a BRAF inhibitor (with or without a MEK inhibitor).
2. Surgical Candidacy (The Paradox)
- Despite having "unresectable" overall disease, the patient must have at least one tumor lesion that can be safely and surgically removed.
- This resection is not for cure; it is strictly to harvest tissue for TIL extraction.
- If no lesion is safely accessible, TIL therapy is generally not possible.
3. Organ Function & Performance Status
- Performance Status: Generally ECOG 0 or 1 (fully active or restricted in strenuous activity but ambulatory).
- Cardiac: Adequate heart function (e.g., Left Ventricular Ejection Fraction ≥ 50%) to withstand IL-2 fluid shifts.
- Pulmonary: Adequate lung function to tolerate potential capillary leak syndrome.
- Hepatic/Renal: Normal or near-normal liver and kidney function to process lymphodepleting chemotherapy and IL-2.
4. Absence of Exclusionary Factors
- No active, uncontrolled bacterial, viral, or fungal infections.
- No active, severe autoimmune diseases requiring systemic immunosuppression.
- No untreated, active brain metastases (treated and stable brain mets may be evaluated on a case-by-case basis).
- No history of severe, life-threatening reactions to prior immunotherapies.
Important Note on "Gray Areas": Medicine is not always black and white. A patient who is borderline on one criterion (e.g., slightly reduced kidney function or a single stable brain metastasis) may still be evaluated by a specialized multidisciplinary tumor board. However, the core requirements (prior treatment failure and surgical resectability) are rarely waived.
What Records Will the Center Need for Evaluation?
To determine if you meet these criteria, a certified TIL center will require a comprehensive, up-to-date medical file. Gathering these in advance can accelerate the review process:
- Pathology Reports: Confirming melanoma diagnosis, including BRAF V600 mutation status and other relevant biomarkers.
- Recent Imaging: PET/CT or MRI scans (typically within the last 4–8 weeks) to assess overall tumor burden and, crucially, to identify if any lesion is safely resectable.
- Treatment History Summary: A detailed timeline of all prior systemic therapies (immunotherapy, targeted therapy), including start/end dates, dosages, and documented radiographic responses or progression.
- Clinical & Organ Function Tests: Recent comprehensive metabolic panel (CMP), complete blood count (CBC), echocardiogram (ECHO), and pulmonary function tests (PFTs).
- Physician Notes: Recent clinic notes detailing your current symptoms, performance status (ECOG), and any comorbidities.
Unspoken Questions: Addressing Your Concerns
"What if I am denied eligibility?"
A denial is not a judgment on your will to fight; it is a protective measure based on clinical data showing that the risks (e.g., severe IL-2 toxicity or surgical complications) outweigh the potential benefits for your specific physiology. If denied, your oncologist will immediately pivot to discussing "Plan B" options, which may include clinical trials, alternative systemic therapies, or supportive care.
"Can my local doctor help me get approved?"
Your local oncologist plays a vital role. They cannot "approve" you for TIL therapy, but they can ensure your medical records are complete, your organ function is optimized, and any active infections are treated before your file is sent to the TIL center. A well-prepared file significantly improves the efficiency of the evaluation.
"What if my tumor is in a difficult location?"
This is where the "Surgical Candidacy" pillar is tested. A specialized surgical oncologist at the TIL center will review your imaging to determine if a safe resection is feasible. If the tumor is wrapped around vital structures or the surgery poses an unacceptable risk, you will likely be deemed ineligible for TIL therapy.
How CancerCareE Supports Your Evaluation
CancerCareE is strictly an independent information and introduction platform. We do not review medical records, determine eligibility, or guarantee acceptance.
Our role is to help you:
- Understand these complex eligibility criteria in plain language.
- Identify which certified centers or clinical trials may align with your specific diagnosis and location.
- Facilitate an introduction to a partner institution or medical facilitation agency, who will then guide you through their specific record-submission process.
Related Resources
Continue Your Research:
Evidence & Review:
Last reviewed: August 2026
Clinical scope: Eligibility criteria for TIL therapy (lifileucel) in advanced melanoma.
Evidence sources: FDA prescribing information for Amtagvi, pivotal trial data (C-144-01), and standard oncologic practice guidelines.
This content is for general educational purposes only and does not replace professional medical advice or formal clinical evaluation.
Frequently Asked Questions
No. Currently, FDA-approved TIL therapy (Amtagvi) is strictly indicated for patients who have already progressed on a PD-1 blocking antibody (and BRAF/MEK inhibitors if applicable). It is not approved as a first-line treatment.
"Unresectable" means the overall disease cannot be completely removed for a cure. However, TIL therapy requires a limited surgical resection of just one accessible lesion to harvest immune cells. If no lesion can be safely removed, TIL therapy is not possible.
Once a certified center receives your complete medical records, the multidisciplinary review (involving medical oncology, surgical oncology, and sometimes cardiology/pulmonology) typically takes 1 to 3 weeks, depending on the complexity of the case and the completeness of the records.
Request an Information-Based Introduction
If you believe you may meet these criteria, CancerCareE can help connect you with the right partners to begin a formal clinical evaluation.
CancerCareE does not provide medical advice, determine eligibility, or make treatment recommendations. Eligibility and treatment decisions are made only by licensed clinicians at the receiving institution.